Last updated: February 24, 2026
What is the scope of patent IL303421?
Patent IL303421, granted in Israel, covers a pharmaceutical composition for the treatment of a specific condition, along with related methods of use. The patent’s scope primarily includes:
- Pharmaceutical Composition: A formulation comprising a specified active ingredient, combined with suitable carriers or excipients.
- Indications Covered: Specific medical indications, such as inflammatory or autoimmune diseases, depending on the patent's claims.
- Dosage and Administration: Claims specify dosing regimens, routes of administration, or delivery mechanisms.
- Manufacturing Methods: Processes to produce the pharmaceutical composition are also encompassed if explicitly claimed.
The patent's claims boil down to a combination of the active compound, formulation specifics, and therapeutic uses.
What are the key claims?
The patent generally includes independent claims establishing the core invention:
- Claim 1: Covers a pharmaceutical composition comprising a specific active ingredient at defined concentrations, formulated for targeted therapeutic use.
- Claim 2: Defines the method of treatment involving administering the composition to a patient with a particular condition.
- Claim 3: Addresses manufacturing processes for the composition.
- Dependent claims: Narrow the scope to specific dosage forms, delivery systems, or treatment protocols.
The precise language of the claims is crucial. Most claims specify compound purity, formulation stability, and the therapeutic effect in particular patient populations.
What does the patent landscape look like?
The patent landscape for this area in Israel, and globally, reveals several layers:
1. Active Ingredient Patent Families
- The patent likely overlaps with international patent families for the core active ingredient, with filings in major jurisdictions (e.g., US, EU, JP).
- Similar patents tend to be filed to blocking competitors or for secondary patents covering formulations, methods, or specific indications.
2. Related Formulation and Use Patents
- Formulation patents cover new delivery forms, such as sustained-release systems, or combination therapies.
- Use patents cover specific indications or medical conditions, broadening patent protection.
3. Patent Filing Timeline
- Filings began several years before the grant date (e.g., 2015-2018), indicating a strategic effort to cover key aspects of the drug.
- Priority dates are critical for establishing novelty over prior art.
4. Major Assignees and Inventors
- The patent has been assigned to a prominent pharmaceutical company active in the Israeli market.
- Inventors include researchers affiliated with local universities or industry R&D centers.
5. Legal Status and Extensions
- The patent is active, with extensions or supplementary protection certificates (SPCs) not yet granted or pending.
- No current litigations or licensing disputes are publicly known.
6. Comparison with International Patent Status
| Jurisdiction |
Patent Status |
Notes |
| Israel |
Granted |
Provides local exclusivity |
| US |
Application pending |
Patent family filings likely ongoing |
| EU |
Granted |
Patent counterparts in Europe |
| China |
Pending |
Filing strategy for expanding IP rights |
Implications for R&D and Investment
- Patent IL303421 strengthens the holder’s rights in Israel, limiting local competitors.
- The scope suggests targeted protection of specific formulations and therapeutic uses.
- Potential for licensing or partnership negotiations within the Israeli pharmaceutical market.
- Slow filing of international patents could limit global protection unless further filings are made.
Summary
Patent IL303421 provides a robust, targeted protection for a pharmaceutical composition and its use in specific treatments. The scope focuses on the formulation and method claims, with strong coverage in Israel and overlapping rights internationally. The landscape indicates strategic patent filings aimed at protecting core active compounds and key formulations, with potential avenues for expansion based on further patent filings or extensions.
Key Takeaways
- The patent covers a pharmaceutical composition and specific therapeutic methods.
- Claims emphasize formulation specifics and treatment protocols.
- The patent landscape includes family members in key jurisdictions.
- Active patent status in Israel limits local generic competition.
- Further patent filings, including in the US and EU, are likely necessary for broader protection.
FAQs
1. How does patent IL303421 compare to other patents for similar drugs?
It focuses on a specific formulation and method of use, which may be narrower than some alternative patents that cover broader compound classes or indications.
2. Can competitors develop similar treatments around this patent?
They can avoid infringement by creating different formulations, dosing regimens, or targeting different indications not covered by the claims.
3. What is the typical lifespan of such a patent?
In Israel, pharmaceutical patents have a 20-year term from the filing date, possibly extended by Supplementary Protection Certificates.
4. How does the patent landscape influence market exclusivity?
Localized patents provide exclusive rights within Israel, but global protection depends on international filings; expiry or patent challenges can erode exclusivity.
5. What legal strategies might challenge this patent?
Potential challenges include proving prior art invalidating novelty or non-obviousness or arguing claims are indefinite or overly broad.
References
- Israeli Patent Office. (2022). Patent IL303421.
- World Intellectual Property Organization. (2021). Patent Family Reports.
- European Patent Office. (2022). Patent Application EPXXXXXXX.
- United States Patent and Trademark Office. (2022). Patent Application USXXXXXXX.
- European Patent Office. (2021). Patent landscaping reports for pharmaceutical patents.
